These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 29877137)
1. Comparative Effectiveness of Conservative Management Compared to Cryotherapy in Localized Prostate Cancer Patients. Shah S; Young HN; Cobran EK Am J Mens Health; 2018 Sep; 12(5):1681-1691. PubMed ID: 29877137 [TBL] [Abstract][Full Text] [Related]
2. Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Roberts CB; Jang TL; Shao YH; Kabadi S; Moore DF; Lu-Yao GL Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):313-9. PubMed ID: 21519347 [TBL] [Abstract][Full Text] [Related]
3. Effects of Focal vs Total Cryotherapy and Minimum Tumor Temperature on Patient-reported Quality of Life Compared With Active Surveillance in Patients With Prostate Cancer. Werneburg GT; Kongnyuy M; Halpern DM; Salcedo JM; Chen C; LeSueur A; Kosinski KE; Schiff JT; Corcoran AT; Katz AE Urology; 2018 Mar; 113():110-118. PubMed ID: 29277657 [TBL] [Abstract][Full Text] [Related]
4. The role of focal therapy in the management of localised prostate cancer: a systematic review. Valerio M; Ahmed HU; Emberton M; Lawrentschuk N; Lazzeri M; Montironi R; Nguyen PL; Trachtenberg J; Polascik TJ Eur Urol; 2014 Oct; 66(4):732-51. PubMed ID: 23769825 [TBL] [Abstract][Full Text] [Related]
5. Salvage cryotherapy for local recurrence after radiotherapy for prostate cancer. Kvorning Ternov K; Krag Jakobsen A; Bratt O; Ahlgren G Scand J Urol; 2015 Apr; 49(2):115-9. PubMed ID: 25428754 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. Williams SB; Lei Y; Nguyen PL; Gu X; Lipsitz SR; Yu HY; Kowalczyk KJ; Hu JC BJU Int; 2012 Jul; 110(2 Pt 2):E92-8. PubMed ID: 22192688 [TBL] [Abstract][Full Text] [Related]
7. Erectile function after stereotactic body radiotherapy for localized prostate cancer. Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895 [TBL] [Abstract][Full Text] [Related]
8. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer. Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842 [TBL] [Abstract][Full Text] [Related]
10. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up. Ferrer M; Guedea F; Suárez JF; de Paula B; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Boladeras A; Ayala A; Craven-Bratle J; Ávila M; Cunillera O; Pardo Y; Alonso J; Aguiló F; Radiother Oncol; 2013 Aug; 108(2):306-13. PubMed ID: 23849168 [TBL] [Abstract][Full Text] [Related]
11. Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. Tay KJ; Polascik TJ; Elshafei A; Cher ML; Given RW; Mouraviev V; Ross AE; Jones JS J Endourol; 2016 Jan; 30(1):43-8. PubMed ID: 26414656 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. Mendez MH; Passoni NM; Pow-Sang J; Jones JS; Polascik TJ J Endourol; 2015 Oct; 29(10):1193-8. PubMed ID: 26058496 [TBL] [Abstract][Full Text] [Related]
13. Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre's experience. Philippou P; Yap T; Chinegwundoh F Urol Int; 2012; 88(2):137-44. PubMed ID: 22285952 [TBL] [Abstract][Full Text] [Related]
14. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547 [TBL] [Abstract][Full Text] [Related]
16. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365 [TBL] [Abstract][Full Text] [Related]
17. Associations of multimorbidity and patient-reported experiences of care with conservative management among elderly patients with localized prostate cancer. Fiano RM; Merrick GS; Innes KE; Mattes MD; LeMasters TJ; Shen C; Sambamoorthi U Cancer Med; 2020 Aug; 9(16):6051-6061. PubMed ID: 32628817 [TBL] [Abstract][Full Text] [Related]
18. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer. Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT; Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397 [TBL] [Abstract][Full Text] [Related]
19. Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. Wagner AA; Cheng PJ; Carneiro A; Dovirak O; Khosla A; Taylor KN; Crociani CM; McAnally KC; Percy A; Dewey LE; Sanda MG; Chang P J Urol; 2017 Jan; 197(1):109-114. PubMed ID: 27475967 [TBL] [Abstract][Full Text] [Related]